参附注射液通过TGF-β/Smads信号通路对心力衰竭的心脏保护作用

Cardioprotection against Heart Failure by Shenfu Injection via TGF-/Smads Signaling Pathway.

作者信息

Ni Jingyu, Shi Yang, Li Lan, Chen Jingrui, Li Lingyan, Li Min, Zhu Jinqiang, Zhu Yan, Fan Guanwei

机构信息

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.

Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China.

出版信息

Evid Based Complement Alternat Med. 2017;2017:7083016. doi: 10.1155/2017/7083016. Epub 2017 Jun 15.

OBJECTIVE

To explore the potential cardioprotective mechanism of Shenfu injection (SFI) against heart failure (HF) by attenuating myocardial fibrosis and cardiac remodeling.

METHODS AND RESULTS

Four weeks after myocardial infarction (MI), adult male Sprague Dawley rats were randomized for 4-week treatment with Valsartan, SFI, or vehicle. Echocardiography and hemodynamics were applied to evaluate cardiac functions. Myocardia of coronary artery ligated (CAD) rats were observed to investigate changes in cardiac structure and function. Our findings suggest that treatment with SFI could inhibit progression of myocardial fibrosis and attenuate cardiac remodeling. In addition, SFI decreased expression of Smad2 and Smad3, while increasing the expression of Smad7 through regulation of TGF-/Smads signaling pathway.

CONCLUSION

Treatment with SFI in Sprague Dawley rats improves ventricular structure and function and reduces cardiac fibrosis by ameliorating TGF-/Smads signaling pathway after ventricular remodeling.

目的

通过减轻心肌纤维化和心脏重塑，探讨参附注射液（SFI）对心力衰竭（HF）的潜在心脏保护机制。

方法与结果

成年雄性Sprague Dawley大鼠在心肌梗死（MI）四周后，随机分为缬沙坦组、参附注射液组或空白对照组，进行为期4周的治疗。应用超声心动图和血流动力学评估心脏功能。观察冠状动脉结扎（CAD）大鼠的心肌，以研究心脏结构和功能的变化。我们的研究结果表明，参附注射液治疗可抑制心肌纤维化进展并减轻心脏重塑。此外，参附注射液通过调节TGF-β/Smads信号通路，降低Smad2和Smad3的表达，同时增加Smad7的表达。